204 related articles for article (PubMed ID: 32909660)
1. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Austin CD; Gonzalez Edick M; Ferrando RE; Solon M; Baca M; Mesh K; Bradding P; Gauvreau GM; Sumino K; FitzGerald JM; Israel E; Bjermer L; Bourdin A; Arron JR; Choy DF; Olsson JK; Abreu F; Howard M; Wong K; Cai F; Peng K; Putnam WS; Holweg CTJ; Matthews JG; Kraft M; Woodruff PG;
Clin Exp Allergy; 2020 Dec; 50(12):1342-1351. PubMed ID: 32909660
[TBL] [Abstract][Full Text] [Related]
2. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
Noonan M; Korenblat P; Mosesova S; Scheerens H; Arron JR; Zheng Y; Putnam WS; Parsey MV; Bohen SP; Matthews JG
J Allergy Clin Immunol; 2013 Sep; 132(3):567-574.e12. PubMed ID: 23726041
[TBL] [Abstract][Full Text] [Related]
3. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
Scheerens H; Arron JR; Zheng Y; Putnam WS; Erickson RW; Choy DF; Harris JM; Lee J; Jarjour NN; Matthews JG
Clin Exp Allergy; 2014 Jan; 44(1):38-46. PubMed ID: 24131304
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
[TBL] [Abstract][Full Text] [Related]
5. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.
Corren J; Szefler SJ; Sher E; Korenblat P; Soong W; Hanania NA; Berman G; Brusselle G; Zitnik R; Natalie CR; Sun L; Siu K; Wu WS; Lio P; Armstrong AW
J Allergy Clin Immunol Pract; 2024 May; 12(5):1215-1224.e3. PubMed ID: 38360213
[TBL] [Abstract][Full Text] [Related]
6. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
[TBL] [Abstract][Full Text] [Related]
7. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell RJ; Chachi L; FitzGerald JM; Backer V; Olivenstein R; Titlestad IL; Ulrik CS; Harrison T; Singh D; Chaudhuri R; Leaker B; McGarvey L; Siddiqui S; Wang M; Braddock M; Nordenmark LH; Cohen D; Parikh H; Colice G; Brightling CE;
Lancet Respir Med; 2018 Jul; 6(7):499-510. PubMed ID: 29793857
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.
Korenblat P; Kerwin E; Leshchenko I; Yen K; Holweg CTJ; Anzures-Cabrera J; Martin C; Putnam WS; Governale L; Olsson J; Matthews JG
Respir Med; 2018 Jan; 134():143-149. PubMed ID: 29413502
[TBL] [Abstract][Full Text] [Related]
9. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma.
Liu Y; Zhang S; Chen R; Wei J; Guan G; Zhou M; Dong N; Cao Y
Allergy Asthma Proc; 2018 Sep; 39(5):332-337. PubMed ID: 30153886
[TBL] [Abstract][Full Text] [Related]
11. Lebrikizumab treatment in adults with asthma.
Corren J; Lemanske RF; Hanania NA; Korenblat PE; Parsey MV; Arron JR; Harris JM; Scheerens H; Wu LC; Su Z; Mosesova S; Eisner MD; Bohen SP; Matthews JG
N Engl J Med; 2011 Sep; 365(12):1088-98. PubMed ID: 21812663
[TBL] [Abstract][Full Text] [Related]
12. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
Hanania NA; Noonan M; Corren J; Korenblat P; Zheng Y; Fischer SK; Cheu M; Putnam WS; Murray E; Scheerens H; Holweg CT; Maciuca R; Gray S; Doyle R; McClintock D; Olsson J; Matthews JG; Yen K
Thorax; 2015 Aug; 70(8):748-56. PubMed ID: 26001563
[TBL] [Abstract][Full Text] [Related]
13. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
16. Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma.
Agrawal S; Townley RG
Expert Opin Biol Ther; 2014 Feb; 14(2):165-81. PubMed ID: 24283478
[TBL] [Abstract][Full Text] [Related]
17. Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma.
Nakamura Y; Sugano A; Ohta M; Takaoka Y
PLoS One; 2017; 12(11):e0188407. PubMed ID: 29155876
[TBL] [Abstract][Full Text] [Related]
18. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
19. Lebrikizumab for the treatment of asthma.
Antoniu SA
Expert Opin Investig Drugs; 2016 Oct; 25(10):1239-49. PubMed ID: 27554950
[TBL] [Abstract][Full Text] [Related]
20. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma.
Ward C; Pais M; Bish R; Reid D; Feltis B; Johns D; Walters EH
Thorax; 2002 Apr; 57(4):309-16. PubMed ID: 11923548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]